Title

Towards the Total Synthesis of 5-bromo-8-methoxy-1-methyl-β-carboline as a Potential Anti-Leukemic Agent

Presenter Information

Katie Frazier
Rane Creasy

Document Type

Oral Presentation

Location

SURC Ballroom C/D

Start Date

16-5-2013

End Date

16-5-2013

Abstract

In the United States, cancer accounts for 1 in 4 deaths annually, and leukemia, a type of cancer, is the number one cause of cancer related deaths in children ages 1-14 years. Current treatments are associated with numerous side effects, and consequently, new anti-leukemic drug candidates should be pursued. A compound known as 5-bromo-8-methoxy-1-methyl-β-carboline has been shown to exhibit moderate activity against a model leukemia cell line. However, the organism from which this compound is derived, Pterocella vesiculosa, produces it in very small quantities. Continued testing for biological, anti-leukemic properties requires a more efficient, cost-effective production route. The aim of this project is to complete the first total synthesis of 5-bromo-8-methoxy-1-methyl-β-carboline by completing a series of organic chemistry reactions. Once synthesized, the product will be characterized by carbon and proton nuclear magnetic resonance spectroscopy (1H and 13 C NMR), infrared spectroscopy (IR), and thin layer chromatography (TLC). Successful synthesis of this potentially anti-leukemic drug could ultimately provide patients with new avenues of cheaper, more powerful, less toxic chemotherapies.

Poster Number

44

Faculty Mentor(s)

Stephen Chamberland

Additional Mentoring Department

Chemistry

This document is currently not available here.

Share

COinS
 
May 16th, 8:20 AM May 16th, 10:50 AM

Towards the Total Synthesis of 5-bromo-8-methoxy-1-methyl-β-carboline as a Potential Anti-Leukemic Agent

SURC Ballroom C/D

In the United States, cancer accounts for 1 in 4 deaths annually, and leukemia, a type of cancer, is the number one cause of cancer related deaths in children ages 1-14 years. Current treatments are associated with numerous side effects, and consequently, new anti-leukemic drug candidates should be pursued. A compound known as 5-bromo-8-methoxy-1-methyl-β-carboline has been shown to exhibit moderate activity against a model leukemia cell line. However, the organism from which this compound is derived, Pterocella vesiculosa, produces it in very small quantities. Continued testing for biological, anti-leukemic properties requires a more efficient, cost-effective production route. The aim of this project is to complete the first total synthesis of 5-bromo-8-methoxy-1-methyl-β-carboline by completing a series of organic chemistry reactions. Once synthesized, the product will be characterized by carbon and proton nuclear magnetic resonance spectroscopy (1H and 13 C NMR), infrared spectroscopy (IR), and thin layer chromatography (TLC). Successful synthesis of this potentially anti-leukemic drug could ultimately provide patients with new avenues of cheaper, more powerful, less toxic chemotherapies.